[Behavior of high-density lipoproteins in drug lipid-lowering treatment].
Changes in serum lipids, the individual lipoprotein fractions after ultracentrifugation and the apoproteins B, A1 and A2 were studied in 66 patients with primary hypercholesterolemia under treatment with different lipid-lowering agents. After 3 months with dietary treatment alone and a 4-week placebo period the patients were given bezafibrate (3 X 200 mg daily), colestipol (2 X 10 g per day) or probucol (2 X 500 mg daily) for 12 months, followed by another 4-week placebo period at the end of the study. Colestipol showed the best lipid-lowering effect (total and LDL cholesterol were decreased by 20% and 23% respectively) but satisfactory total and LDL cholesterol lowering results were also obtained with the other substances. However, the changes in HDL differed widely among the three substances: bezafibrate increased HDL cholesterol and the HDL apoproteins A1 and A2 significantly, colestipol did not alter these parameters, while probucol treatment was followed by a significant decrease in both HDL-cholesterol and the apoproteins A1 and A2.
D000328:Adult; D001059:Apoproteins / Q000097:blood; D001629:Bezafibrate; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL; D002995:Clofibric Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D003084:Colestipol / Q000008:administration & dosage; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood* / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000008:administration & dosage; D008055:Lipids / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D011341:Probucol / Q000008:administration & dosage
D001059:Apoproteins; D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D008055:Lipids; D008075:Lipoproteins, HDL; D002995:Clofibric Acid; D002784:Cholesterol; D003084:Colestipol; D011341:Probucol; D001629:Bezafibrate
Verhalten der High-density-Lipoproteine (HDL) unter medikamentöser lipidsenkender Behandlung.